Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-05-16

Clinical Trial Update: Vectibix for the Treatment of Anal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update showing completion of Vectibix (panitumumab) for anal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vectibix (panitumumab)

Snippet

Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo | Conditions: Anal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED